Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth

Cancer Research

Volumn 69, Issue 4, 2009, Pages 1324-1333

  Nasarre, Patrick ^a,e   Thomas, Markus ^b,f   Kruse, Karoline ^b   Helfrich, Iris ^b,g   Wolter, Vivien ^b   Deppermann, Carleen ^b   Schadendorf, Dirk ^c,g   Thurston, Gavin ^d   Fiedler, Ulrike ^a,h   Augustin, Hellmut G ^a,b  

^a TUMOR BIOLOGY CENTER   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d REGENERON PHARMACEUTICALS INC   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f ROCHE DIAGNOSTICS GMBH   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h PROQINASE GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOPOIETIN 2; DESMIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CARCINOGENESIS; CELL MATURATION; CONTROLLED STUDY; LEWIS CARCINOMA; MELANOMA; MOUSE; NONHUMAN; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR GROWTH;

ANGIOPOIETIN-2; ANIMALS; CELL DIVISION; CELL LINE, TUMOR; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROCIRCULATION; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60549103097     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3030     Document Type: Article

References (51)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Kesisis G, Broxterman H, Giaccone G. Angiogenesis inhibitors. Drug selectivity and target specificity. Curr Pharm Des 2007;13:2795-809.
3. Ng YS, Krilleke D, Shima DT. VEGF function in vascular pathogenesis. Exp Cell Res 2006;312:527-37.
4. Baka S, Clamp AR, Jayson GC. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 2006;10:867-76.
5. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
6. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2receptor, by secretion-trap expression cloning. Cell 1996;87:1161-9.
7. Pfaff D, Fiedler U, Augustin HG. Emerging roles of the angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking. J Leukoc Biol 2006;80:719-26.
8. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
9. Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angio-poietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A 2002;99:8219-24.
10. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004;103:4150-6.
11. Fiedler U, Krissl T, Koidl S, et al. Angiopoietin-1 and angiopoietin-2share the same binding domains in the Tie-2receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 2003;278:1721-7.
12. I integrin-mediated pathway. Cancer Res 2007;67:4254-63.
13. I integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. JCell Biol 2005;170:993-1004.
14. Carlson TR, Feng Y, Maisonpierre PC, Mrksich M, Morla AO. Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 2001;276:26516-25.
15. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2ligand angiopoietin-2destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005;118:771-80.
16. Daly C, Pasnikowski E, Burova E, et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci U S A 2006;103:15491-6.
17. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997;277:48-50.
18. Peters S, Cree IA, Alexander R, et al. Angiopoietin modulation of vascular endothelial growth factor: effects on retinal endothelial cell permeability. Cytokine 2007;40:144-50.
19. Zhang L, Yang N, Park JW, et al. Tumor-derived vascular endothelial growth factor up-regulates angio-poietin-2in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003;63:3403-12.
20. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angio-poietin-2sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med 2006;12:235-9.
21. Ahmad SA, Liu W, Jung YD, et al. Differential expression of angiopoietin-1 and angiopoietin-2in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 2001;92:1138-43.
22. Wurmbach JH, Hammerer P, Sevinc S, Huland H, Ergun S. The expression of angiopoietins and their receptor Tie-2in human prostate carcinoma. Anticancer Res 2000;20:5217-20.
23. Tsutsui S, Inoue H, Yasuda K, et al. Angiopoietin 2expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 2006;98:261-6.
24. Zagzag D, Hooper A, Friedlander DR, et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2as an early marker of tumor angiogen-esis. Exp Neurol 1999;159:391-400.
25. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2is related to tumor angiogen-esis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001;61:2145-53.
26. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507-16.
27. Sarraf-Yazdi S, Mi J, Moeller BJ, et al. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J Surg Res 2008;146:16-23.
28. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2sug-gests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-66.
29. Bazhin AV, Schadendorf D, Willner N, et al. Photoreceptor proteins as cancer-retina antigens. Int J Cancer 2007;120:1268-76.
30. Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007;117:2766-77.
31. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286:2511-4.
32. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002;99:11205-10.
33. Kidoya H, Ueno M, Yamada Y, et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 2008;27:522-34.
34. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined bypericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125:1591-8.
35. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002;3:411-23.
36. Cao Y, Sonveaux P, Liu S, et al. Systemic over-expression of angiopoietin-2promotes tumor micro-vessel regression and inhibits angiogenesis and tumor growth. Cancer Res 2007;67:3835-44.
37. Reiss Y, Droste J, Heil M, et al. Angiopoietin-2impairs revascularization after limb ischemia. Circ Res 2007;101:88-96.
38. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie2expression and phos-phorylation in angiogenic and quiescent adult tissues. Circ Res 1997;81:567-74.
39. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
40. Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 1998;78:1385-94.
41. Hammes HP, Lin J, Wagner P, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004;53:1104-10.
42. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005;97:512-23.
43. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-5.
44. Kobayashi H, BeBusk LM, Babichev YO, Dumont DJ, Lin PC. Hepatocyte growth factor mediates angiopoie-tin-induced smooth muscle cell recruitment. Blood 2006;108:1260-6.
45. Iivanainen E, Nelimarkka L, Elenius V, et al. Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J 2003;17:1609-21.
46. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000.
47. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003;314:15-23.
48. Nehls V, Drenckhahn D. Heterogeneity of microvascular pericytes for smooth muscle type α-actin. J Cell Biol 1991;113:147-54.
49. Hamzah J, Jugold M, Kiessling F, et al. Vascular normalization in RGS5-deficient tumours promotes immune destruction. Nature 2008;453:410-4.
50. Christian S, Winkler R, Helfrich I, et al. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. Am J Pathol 2008;172:486-94.
51. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.